Current stock page

Stock Analysis

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis

Neurocrine Biosciences, Inc. (NBIX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

NBIX Stock Analysis Summary

Neurocrine Biosciences, Inc. (NBIX) currently has an AIQ Score of 74/100, indicating a bullish setup. Quality is the strongest factor at 79/100. Risk is the weakest current factor at 69/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

NBIX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$167.40
AIQ Score74/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$17.01B
P/E Ratio (TTM)24.02
Forward P/E—
EPS (Q3 FY2026)$2.03
Revenue (Q3 FY2026)$1.12B
Dividend Yield (TTM)0.00%
Beta0.7
Volume1.38M
52-week range$122.14-$186.12
RSI 1464.45
50-Day SMA$148.58
200-Day SMA$148.88
Analyst Price Target$206.80
Next EarningsFeb 10, 2027
As of Nov 13, 2026 · Market close

NBIXNeurocrine Biosciences, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$167.40−$2.00 (−1.18%)

Latest quote

  • Momentum
    70
  • Value
    77
  • Quality
    79
  • Risk resilience
    69
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

NBIX Stock Analysis Summary

Neurocrine Biosciences, Inc. (NBIX) currently has an AIQ Score of 74/100, indicating a bullish setup. Quality is the strongest factor at 79/100. Risk resilience is the weakest current factor at 69/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, NBIX has AIQ Score of 74/100 with Quality base of 79/100 and fading Risk resilience at 69/100. Wait for component alignment before adding exposure.

Healthcare · -1.18% stock move · NBIX classified in Biotechnology.

Current Evidence

BullishNBIX is in a bullish AIQ regime; Quality is the strongest visible factor at 79/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is NBIX Bullish or Bearish Right Now?

NBIX currently has a bullish overall setup. Quality is the strongest factor at 79/100, while Risk Resilience is weakest at 69/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 79/100.
  • - Momentum is constructive at 70/100.
  • - Risk Resilience is supportive at 69/100.
  • - Price is +12.67% above its 50-day SMA.
  • - Analyst target implies +23.54% upside from the latest quote.
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

NBIX's Technical Analysis Consensus is currently Strong Buy, with 35 buy, 7 neutral, and 4 sell votes. NBIX's 14-day RSI is 64.45, which places the stock in a constructive momentum range. NBIX's beta is 0.7, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in NBIX?

The largest recent change in NBIX is Momentum moving up by 9.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+3.0
Momentum
+9.0
Quality
+0.0
Risk
-1.0

What Would Change the NBIX Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

NBIX Decision Framework

Public evidence layers, setup checks, and risk context for Neurocrine Biosciences, Inc..

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis

Neurocrine Biosciences, Inc. has an AIQ Score of 74/100 in a Bullish regime. Quality is strongest at 79/100. Beta is 0.7, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextNBIX is in a Bullish AIQ regime with score 74/100.
Signal ConflictThe primary conflict is that quality leads at 79/100 while risk lags at 69/100.
Factor EvidenceMomentum 70/100 · Value 77/100 · Quality 79/100 · Risk 69/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 79/100.

TimingPass

Momentum is 70/100 and RSI (14) is 64.4.

Regime fitPass

NBIX is in a Bullish regime at 74/100.

Risk controlPass

Risk factor is 69/100 with beta 0.7 and annual volatility 35.22%.

ConflictPass

Current conflict: quality leads at 79/100 while risk lags at 69/100.

AIQ Score
74/100
Price
$167.40
Beta
0.7
RSI (14)
64.4

NBIX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

NBIX Fundamentals

NBIX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$1.12B
Net income
$206.5M
Free cash flow
$383.6M
View full NBIX fundamental analysis

NBIX Technical Analysis

NBIX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
64.45
Price vs SMA-50
+12.67%
View full NBIX technical analysis

NBIX Stock Catalysts

Track NBIX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 10, 2027
Analyst target
$206.80
News items
4
View NBIX earnings and stock catalysts

NBIX Dividend Analysis

NBIX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View NBIX dividend history and analysis

NBIX Financial Data

NBIX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$1.12B
EPS
$2.03
Periods
8
View NBIX financials

NBIX Risk Analysis

NBIX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.7
Risk score
69/100
1Y volatility
35.22%
View NBIX risk analysis

NBIX Stock News

NBIX stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read NBIX stock news

NBIX vs Biotechnology Peers

Current peer cohort: NBIX · NKTR · NRIX · NVAX · OCUL. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
NBIX
Current stock
74/10077/10070/10069/1000.4935.22%Current
NKTR
Nektar Therapeutics
39/10047/10025/10041/100-0.1184.03%NBIX vs NKTR
NRIX
Nurix Therapeutics, Inc.
65/10094/10050/10040/1000.6467.30%NBIX vs NRIX
NVAX
Novavax, Inc.
——77/10038/1000.5673.62%NBIX vs NVAX
OCUL
Ocular Therapeutix, Inc.
38/10041/10034/10036/100-0.4576.10%NBIX vs OCUL
Pairwise Compare links: NKTR · NRIX · NVAX · OCULNBIX vs NKTRNBIX vs NRIXNBIX vs NVAXNBIX vs OCULCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a NBIX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for NBIX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
24.02
As of Nov 13, 2026
Revenue growth
41.24%
Gross margin
97.81%
Current debt / equity
0.1
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$1.12B
Quarter net income
$206.5M
Quarter free cash flow
$383.6M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bullish
RSI 14
64.45
MACD
6.99

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
69/100
Beta
0.7
Annual volatility
35.22%
Max drawdown
-27.15%

NBIX Stock FAQ

What is NBIX stock price today?

Neurocrine Biosciences, Inc.'s current stock price is $167.40. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is NBIX bullish or bearish right now?

NBIX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is NBIX's market cap?

NBIX's market cap is $17.01B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is NBIX's current P/E ratio?

NBIX's current P/E ratio is 24.02 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is NBIX's RSI?

NBIX's 14-day RSI is 64.45 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is NBIX above its 50-day and 200-day moving averages?

NBIX is 12.67% from its 50-day SMA and 12.44% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is NBIX's next earnings date?

NBIX's next earnings date is currently listed as Feb 10, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does NBIX pay a dividend?

NBIX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.